Antibodies News and Research

RSS

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

14 Jul 2021

Fungi that live in the gut may be equally important in health and disease

Bacteria's role in gut health has received a lot of attention in recent years. But new research led by scientists at University of Utah Health shows that fungi - another microorganism that lives within us - may be equally important in health and disease.

14 Jul 2021

Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Curia today announced it has entered into a definitive agreement to acquire LakePharma Inc.

From Curia 14 Jul 2021

Fungi and bacteria in the gut may equally impact human health and disease severity

The gut microbiome has received a lot of attention, but research shows that fungi in the gut is also an important microorganism in gut functioning and health.

14 Jul 2021

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel, highly infectious respiratory virus, and the causative agent of coronavirus disease 2019 (COVID-19) pandemic. SARS-CoV-2, which first originated in Wuhan, in Hubei province of China, is a member of the Coronavirdae family and has a large, non-segmented RNA genome.

14 Jul 2021

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Researchers in the United States have demonstrated that the viral spike protein used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells adopts an open conformation exposing novel epitopes that could serve as targets for therapeutic strategies to protect against coronavirus disease 2019 (COVID-19).

14 Jul 2021

Israeli study of breakthrough infections following full BNT-Pfizer vaccination, 40% immunocompromised

Severe forms of coronavirus disease (COVID-19) linked to high mortality rates might arise in a minority of fully-vaccinated individuals with many co-occurring medical conditions, finds a recent study by Israeli researchers published in the journal Clinical Microbiology and Infection.

13 Jul 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

Curia today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization.

From Curia 13 Jul 2021

Colonization by SARS-CoV-2 not synonymous with infection, screening study highlights

A new study released as a preprint on the medRxiv* server throws cold water on this notion, however, by demonstrating that in a set of asymptomatic cases, less than a tenth actually had evidence of SARS-CoV-2 infection. This finding has serious implications for the practices mentioned above, since they may be neither justifiable nor cost-effective as means to break the chain of viral transmission.

13 Jul 2021

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

A recent study published in the MDPI journal, Pathogens, describes a coronavirus peptide vaccine antigen in the form of nanodiamond-based formulations, that demonstrated a robust and long-lasting immune response. The nanodiamonds proved to be a powerful and versatile platform for antigen conjugation. This could make it a safe and effective strategy for the production of off-the-shelf vaccines against multiple coronaviruses.

13 Jul 2021

Selective immunotoxins may help treat liver fibrosis

Chronic alcohol abuse and hepatitis can injure the liver and lead to fibrosis, the buildup of collagen and scar tissue. As a potential approach to treating liver fibrosis, University of California San Diego School of Medicine researchers and their collaborators are looking for ways to stop liver cells from producing collagen.

12 Jul 2021

Study could guide future treatment of multisystem inflammatory syndrome in children

Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds.

12 Jul 2021

Millions of COVID-19 cases went undetected in the first six months of the pandemic, finds study

A new report published in the journal Science Translational Medicine estimates that potentially 16.8 million Americans were infected but not officially diagnosed with SARS-CoV-2 by July 2020. In addition, the results suggest there were nearly five undetected coronavirus cases for every diagnosed coronavirus infection in the first six months of the pandemic.

12 Jul 2021

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Researchers from Switzerland recently investigated humoral and cell-mediated immune responses to mRNA-based vaccines in patients undergoing treatment with CD20-B-cell depleting agents for autoimmune diseases, transplantation, or malignancy.

12 Jul 2021

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

Multivalent protein-based minibinders hold great promise as potential prophylactic and treatment agents, as they can retain their activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. This was revealed in a recent tour-de-force research study currently available on the bioRxiv* preprint server while the article undergoes the peer review process.

11 Jul 2021

Antibodies News and Research

New OMV-based COVID-19 vaccine candidate proves effective in mice

Fungi that live in the gut may be equally important in health and disease

Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Fungi and bacteria in the gut may equally impact human health and disease severity

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Israeli study of breakthrough infections following full BNT-Pfizer vaccination, 40% immunocompromised

Neutralizing aptamers block SARS-CoV-2 infection in vitro

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

Colonization by SARS-CoV-2 not synonymous with infection, screening study highlights

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

Selective immunotoxins may help treat liver fibrosis

Study could guide future treatment of multisystem inflammatory syndrome in children

Millions of COVID-19 cases went undetected in the first six months of the pandemic, finds study

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo